New medicine for insomnia! Eisai double-acting orexin receptor antagonist Dayvigo (lemborexant) is launched in the US!
2020-06-16
Japanese pharmaceutical company Eisai recently announced the launch of Dayvigo (lemborexant), a new drug for insomnia, in the US market for the treatment of adult insomnia. It is estimated that about 30% of adults worldwide have symptoms of insomnia, many of which last for months to years.
Dayvigo's active pharmaceutical ingredient is lemborexant, which is an orexin receptor antagonist that inhibits orexin signaling through competitive binding to orexin receptors (OX1R and OX2R). Orexin is a chemical substance naturally produced by the hypothalamus and is involved in sleep and wakefulness.
